Method for producing 1-phenyl-2-aminoethanol derivatives or pharmaceutically acceptable salts thereo

专利摘要:
The invention concerns compounds of the formula:-R1.CH(OH).CH2NH. CR2R3. A1.NH. CO.CHR4.A2. NR5.Q I wherein R1 is 3,4-bis [(3-8C)alkanoyloxy] -phenyl, 3,5-bis[(3-8C)alkanoyloxy] phenyl, 3-[(3- 8C)alkanoyloxy]- methyl-4- [(3-8C)alkanoyloxy] phenyl, 4-[(3- 8C)alkanoyloxy] -phenyl, 2-chlorophenyl or 3,5-dichloro-4-aminophenyl; R2 and R are independently hydrogen or (1-4C)alkyl; A1 is (1-4C)alkylene; A2 is a direct bond or (1-4C)-alkylene; R4 is hydrogen, (1-6C)alkyl, phenyl-(1-4C)alkyl or halogenophenyl-(1-4C)alkyl; and R' is (1-6C) alkyl; or R4 and R5 together form (2-5C) alkylene; and Q is (3-12C)-alkanoyl, [(3- 6C)alkoxy]carbonyl, phenylacetyl, phenoxyacetyl, benzoyl or benzyloxycarbonyl, the phenyl rings of which may optionally bear a substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy and trifluoromethyl; and the pharmaceutically acceptable acid-addition salts thereof; processes for their manufacture; and pharmaceutical compositions thereof. The compounds of formula I are topical anti-inflammatory agents. A representative compound is 1-[3,4- bis(pivaloyloxy)phenyl] -2-{2-[(N- phenylacetyl-prolyl) -amino]-1,1- dimethyl- ethylamino}ethanol.
公开号:SU1318151A3
申请号:SU802922105
申请日:1980-05-20
公开日:1987-06-15
发明作者:Джоунс Джерайнт
申请人:Империал Кемикал Индастриз Лимитед (Фирма)；
IPC主号:

专利说明:

113191.51
The invention relates to organic chemistry, namely to the semi-e-- method and the novel derivatives of 1-phenyl-2-am1 -; - ethanol of the general formula
ef 1ek to; 1ora il-n et pe N moki ar SI 3, sl; -l
R CH (OH) "C NHCR RC; H NHLX CHR A NR O
(I)
where R is 3,4- or 3 ,, 5-bis (pivaloalki | si) phenyl5, 4-pivalosh; hydroxyphenyl J, 3-and:; 1-butyryloxymethyl-4 isobutyryloxyf NIL, 3,5-dichloro-4 aminifemyl or 3. 5-bis (n-butyryloxy) phenyl;
R and R are hydrogen or methyl;
R is hydrogen, C
benzyl; to - S., -C-alkyl
-C alkyl 5
or K and R
,, alkylene:
form A - simple SVY31
flax |
Q - phenylacetyl5 phenoxyacte: yl, benzoyl, 4-chlorobenzoyl |, 4-chlorophenyl- T: a: i, tert-butyloxycarbonyl 5,
or their pharmaceutically acceptable mudslides, which have anti-inflammatory properties when used in places of inflammation and can be used in medicine.
The purpose of the invention is the development of DS C - a dull way to obtain new AO ;; - compounds of the formula I, which have a high anti-inflammatory activity.
Examples 1-4p Pac i Bop-bis (pivaloyloxy) phenylglnoxal (1j67 g) and N - (2-amino-2-methylprotoni) - N-phenylacetyl-prolinamide (lj51 g) in acetic acid (h ml) and acetonitrile (20 ml) is stirred for 10 minutes and then treated with sodium dichloride boron hydride (0.6 ::) and the mixture is stirred for 3.5 hours. Then water is added;) (20 ml) and the mixture is extracted with ethyl acetate (3 x 75 ml)., Coe /, the extracted extracts are washed with a saturated solution of sodium chloride, cy: iia r (MgSO4) and evaporated. The residue (3.48 g) was purified by chromatography on silica gel (80 g, size 4acT: -iu 0.04-0.63 mm) using a graph containing 1 vol. H. methanol in 49 vol, chloroform, as eluep-- that. Fractions containing a large amount of tea: - t; the main components are collected and evaporated. The residue is dissolved in chloroform (10 ml) and the solution is acidified
0
0
five
ethereal hydrogen bromide, Solvent-ectal extract and excess hydrogen bromis; is removed by re-dissolving in chloroform with; 1 followed by evaporation. In this way, i-i 3 j4-bis - (pivalo-yloxy) phenyl | -2- 2 (N-phenylacetyl-β-propyl) amino -1 j-dimethylethylamino} ethanol bromide (example 1) as a foam (0.35 g); microanalysis and. found: N dl. NVB need N 6.0%; HLND d 8,8-759 (ZN, broad, NHCO + Mlj); 7.5-7.0 (SH complex aromatic H) (1 H, broad, ZION) j SL-2.7 (6K, complex, CH, N); 3.75 (RPSH singlet) 2z2 -1.8, complex, -CH,;, Clij--) I 1.27 (24H, syn-; -year, CHj),
Using a similar procedure, j} io, starting from the corresponding glyoxal and amiko compound, yields barely
When; h g p 2, 1 - 3,4-bis (Piva-., Oyloxy) fe; ggl -2-- 2- (C-phenoxyacetyl -prolyl) amino 1-dimethyleth -1.chami io ethanol hydrobromide in the form of foam (pkod 20%); Tcpl, microdialysis, found,%; C 54j, 0; H 6 j. 7; NIG SH.OS calculate-,. .U, 4.
PRI me R 3 1 - (3-IsobitI-shokimet uu-4-i shoots Iryloxyfenyl) -2 2- (Y-phenypatseti: 1-prolyl) amino-1 ,, dimethylzythylamino this: - ol bromhydride - warts in the form of a stump; (1: output 12%); j5iMP (b): 3.6-850 (4H, broad, NHCO-NHJ); 7, 6-5.6 (BH, complex, aromatic H); 4.95 4.90 (ZN-, singlet, i-Pr .. lkroky, ZION); 4, (complex; K, 0 + CH, N + (CH,), (11+ -N-CH-CO); 3.65 (singlet; pin CH, CO) 5 2, (4H, complex, -N CH .СНСНл); 1, (18Н, quartet, (СП)., SI -С (СК р ,,,
For example,: - (3 5 5-Dichloro-4-α-amins; damn it:) - 2-2-- K -fecoxy-ai-n-pro.
 dimethyletclam
NMR (o) (3Hj complex, NHCO + + KN,); 7j5-5 ,, 7 (74, complex, aromatic H) I 6.1 (wide,, Q); , 5 (3N: syng .-: et ,, Ph SSN.s5; multi - --let; CnOl-ri; 4 ,, 5 (IH; complex N- -CH-CO); 3, (SI, complex NCH ); 2,, 2-1j6 (41-1, complex: NCH, HCH; CH); 1, 22 (bN, si; g: et. SI ,.).
Do not () & go: e is -.r-iHi re materials gender ;, Chan1T should follow ;. m k)
313
A solution of L-proline (23 g, O, 2 mol) in 2 But sodium hydroxide solution (120 ml) is cooled to 0-5 ° C and treated with the resulting solution of phenylacetyl chloride (34.0 g, 0.22 mol) and 2 n. with a solution of sodium oxide hydrate (120 ml) in ten equal and intermittently portions with vigorous shaking and cooling with ice. The mixture is maintained at an alkaline pH value by adding an additional amount of 2N sodium hydroxide solution, if necessary. the reagents are complete, the mixture is shaken for 15 minutes as a result of which a clear solution is formed, which is acidified to pH 2 by cooling with ice by adding dropwise concentrated hydrochloric acid. The acidic solution is cooled, resulting in the formation of L-phenylacetyl-proline in the form of a solid (46.4 g, mp. 135 - 13b with recrystallization from methanol)
N-phenoxyacetyl-proline is obtained in a dialogical manner as a solid with mp 109-111 ° C.
A mixture of N-phenylacetyl-proline (17.4 g), N-methylmorpholine (7.85 ml) and analytical grade chloroform (60 ml) was stirred at room temperature for 5 minutes. After cooling to -23 ° C, isobutyl chloroformate (9.23 ml) was added quickly over 1 minute. An exothermic reaction occurs and the temperature rises to -15 ° C. The mixture was stirred for 1 minute and then 1,2-diamino-2-methylpropane (7.86 ml) was quickly added; further temperature give
opportunity to rise to room
and stirring is continued for
2h The mixture was then poured into water (50 ml) and the organic layer was separated and removed. The aqueous layer was basified (solid potassium carbonate) and extracted with chloroform (4 X 100 ml). The chloroform extracts were dried (MgSO4) and evaporated under high vacuum to give N - (2-amino-2- -methylpropyl) -K-phenylacetylproline - amide in the form of oil (15.5 g); NMR (s): - (CDC1 |,): 7.7-6.7 (6H, complex, aromatic H + NHCO); 4.5 (1H, complex N-CH-CO); 3.8-2.7 (6H, difficult
514
 CHjN + PhCHj); 3.65 (squarelet, PhCHj); 2.4-1.6 (6H, complex, CHjCHjCH + NH.); 1.0 (6H, singlet, C (CH5) 2).
Using the same procedure, but starting with N-phenoxyacetyl-proline, N - (2-amino-2-methylpropyl) -N-phenoxyacetylprolinamide 6 is obtained as an oil; NMR (ss): 7.7-6.7 (6H, complex, NHCO + aromatic H); (ZN, complex, PhOCHjCO + N-CH-CO); 3.8-2.7 (4H, complex, CHjN); 2.5-1.5 (6H, complex, NCHjCHjCHj + NHj).
. Glyoxal starting materials were prepared as follows.
3,4-bis (Pivaloyloxy) phenylglyoxal. A suspension of 3,4-dioxyacetophenone (13.1 g, 0.08 mol) in chloroform (320 ml) is cooled in an ice bath to 0.5 ° Co. To the stirred suspension for 10 min, add a solution at a time. pivaloyl chloride (19, 2 ml, 0.16 mol) in chloroform (80 ml) and a solution of triethylamine (22.2 ml, 0.16 mol) in chloroform (80 ml) o The reaction mixture was stirred at 0–5 for another 1 h, and then poured into a mixture of 2 n. hydrochloric acid solution (100 ml) and ice (200 g) 4 The mixture was extracted with chloroform (3 x 150 ml) and the extracts were successively washed with water (100 ml) with 10% w / s sodium carbonate solution (100 ml), water (100 ml) and brine (100 ml). After drying (MgSO4), the combined extracts are evaporated, resulting in a crude 3,4-bis (pivaloyloxy) acetophenone as an oil (23, 1 g), which is used without purification.
A solution of bromine (3.15 ml, 0.061 mol) in chloroform (50 ml) is added dropwise at room temperature. a stirred solution of 3,4-bis (pivalo-yloxy) acetophenone (19.5 g of 0.061 mole and tert-butyl acetate (8.2, ml, 0.06 mol) in chloroform (150 ml) containing catalytic anhydrous aluminum chloride (0.2 g), the reaction mixture is stirred at room temperature for 1 h after the addition is complete, chromatographic silica gel (75 g) is added and the mixture is evaporated under vacuum. The residual solid is added in the upper part of the column of dry chromatographic silica gel (1 kg, previously deactivate, add iem 10% w / v in water
5131
and then equilibrated with 10% w / w solution (5% v / v) of ethyl acetate in toluene. The column was eluted with a 5% solution (1100 ml) of ethyl acetate in toluene. The column is then eluted with ethyl acetate (2 X 500 ml) and the collected fractions are examined by thin layer chromatography (those) (on silica plates, which are developed in a 50% mixture of ethyl acetate and trluol). The latter fractions are combined and evaporated, resulting in the formation of 2-bromo-3, 4-bic (pivaloyloxy) acetophenone in the form of an oil (14.2 g), which quickly crystallizes to form a solid with m.p. 66 ° C.
 A solution of 2-bromo-3, 4-bis (pivaloxy) acetophenone (2 g) in dimethyl sulfoxide (10 ml) is held for 18 h at room temperature, then poured into ice-water and extracted with ether (3x50 ml) The ether extracts are washed with water (50 ml) and brine.
(50 ml), dried (MgSO4) and evaporated, whereby 3,4-bis (pivaloyloxy) phenylglyoxal is formed as an oil (1.8 g); IR l) “ax 5 1760 cm (ester), 1690 cm-; (-CO.SNO); (CDClj): 8.2-7.1 (complex, aromatic —H); 1-35 (18H, singlet-C, CH) with
3-Isobutyryloxymethyl-4-isobutyryloxyphenyl-glyoxol. The compound is formed as an oil having a satisfactory IR absorption spectrum, as a result of the oxidation of the corresponding N-bromoacetophenone with dimethylsulfoxide.
0 -Bromoacetophenone was prepared as follows.
Sodium hydride (2.0 g) is added in portions to stirred isobutyric acid (150 ml) over 15 min. Then 3-acetoxymethyl-4-acetoxy-acetophenone (40 g) is added and the mixture is heated to 160 ° C. and maintained at this temperature with stirring for 15 hours. The mixture is concentrated by distillation under reduced pressure, while maintaining a temperature of 160 ° C. The sticky residue is cooled and dissolved in ether (500 ml). The solution was washed with 10% sodium carbonate solution (3x250 ml), one (2 x 500 ml) and a saturated salt solution (250 ml). The organic basics are dried (MgSO4), filtered and lined
A brown oil is formed, which is distilled under high vacuum. As a result, 3-isobutyryloxymethyl-4-isobutyryloxy-acetophenone is obtained as a colorless viscous liquid; NMR (CDCl1): (f) 8.2-7.1 (3N, 1, 2, 4-a-aromatic H lattice); 5.1 (2H, singlet 2.55 + 2.67 (5H, singlet, SOOZ + dushte, SNCO); 1.21 + + 1.15 jCl2H, 2 doublets / J 8.3 C / S /,
(sy) sn
Solution of 3-isobutyryloxymethyl-4-isobutyryloxy-acetophenone (8.8 g)
in dimethylsulfoxide (35 ml), left at room temperature for 2 days and then poured into an excess amount of ice-water mixture. The mixture is extracted with ethyl acetate (3x100 ml).
The extracts are successively washed with a saturated solution of sodium bicarbonate (50 ml), water (3 X 50 ml) and a saturated solution of sodium chloride (50 ml) and then evaporated, resulting in a 3-isobutyryloxymethyl-4-isobutyryloxy- o-br6macetophenon in the form of a mask with satisfactory IR spectrum, it is subjected to cleaning with thin layer
chromatography (SiO: 50% v / v EtOAc (gasoline), bp. BO-ZO C).
4-amino-3 ,, 5-dichlorophenylglyoxal. The compound is obtained in the form of a solid hydrate, so pl. 95-98 with 58% yield
by oxidation of 4-amino-3,5-dichloroacetophenone (12.0 g) with selenium dioxide (10.0 g) in a mixture of dioxane (60 ml) and water (2 ml) for 4 hours and subsequent evaporation
filtered mixture.
Examples 5-28 Using a procedure similar to that described in Example 1, but starting from the corresponding glyoxal and amino compound, the following compounds of formula (I) can be obtained
EXAMPLE 5, 5-bis (Pivaloyloxy) phenyl -2-2-C (1-phenylacetyl-β-prolyl) amino -1,1-dimethylethylamino ethanol hydrobromide as a solid bea; substances (13% yield), so pl. 150-156 s (decomposition); NMR (s /): 8.7-8.0 (3N, complex, NHCO + 7.4-6.6 (8H. Complex, aromatic H); 4.9 1H,
doublet / C / S /, 4,3 (multiplet, N-CH-CO); 4.0-2.7 (complex CH N + HzO); 2.2-1.7 (4H, difficult
N CH CHCH,); 1.3 (24 N, complex CH3).
Example 1- (2-Chlorophenyl) -2- (H-benzoylpiperidine-2-carbonyl) amino -1,1-dimethylethylamino-ethanol hydrobromide as a foam (25% yield), mp. 102 C; NMR (d): 9.3-8.6 (GN,
complex, HE + NKj); 8.1 (triplet, NHCO); 8.0-7.2 (9H, complex, aromatic H); 5.34 1H, doublet / C / S /, CHOHj; 4.2 (1H, complex, N- -CH-CO); 3.7-2.7 (complex,); 1.8-1.0 + 1.3 (12H, complex, + singlet,: NCH CHjCH2CH2 + CH3C). .
EXAMPLE 7., 4-bis (11byaloyl-yloxy) phenyl -2-f 2-C (N-benzoylprrillyl) amino -1,1-dimethylethylamino ethanol bromohydrate as a solid (yield 80%) m.p. 175-179 ° C; NMR (d): 9.2-7.8 (4H, complex, NHCO + + NHj + OH); 7.8-6.8 (8H, complex, aromatic H); 5.24 f2H, doublet / T 8 C / S /, 4.68 (1H, complex,
vN-CH-CO); 4.0-2.7 (6H, complex, CHj); 2.7-1.7 (4H, complex, N- -CHjCH CHj); 1.5 + 1.36 (24 N, dushte + + singlet, СНзС).
Example 8. 1- (2-Chlorophenyl-2- - {2- (N-benzoylprolyl) amino -1,1-dimethylethylamino I ethanol hydrobromide as a foam (yield 30%), mp L. 89 C; NM (s): 9.2-8.2 (4H, complex, NHCO + + NHj OH); 7.8-7.1 (9H, complex, aromatic H); 5.35 flH, doublet / C / S / 4.48 (1H, complex N-CH-CO); 3.8-2.8 (complex, CHjN); 2.4-1.7 (4H, complex,) N CKiCH CH); 1.3 (6H, singlet, CHjC).
PRI me R 9. 1- (2-Chlorophenyl-2- (K-phenylacetylprolyl) amino) -1, 1-dimethylethylamino-ethanol bromo hydrate as a foam (yield 44%), mp. / -78 ° C; NMR (sG): 9.2-8.1 (4H, complex, NHCO + N + OH); 7.8-7, G (9H, complex, aromatic, H); 5.3 C1H, doublet / C / S /, 4.3 (1H, complex N — CH — CO); 3.8-2.8 (complex, CHjN); 3.68 (singlet,); 2.2-1.6 (4H, complex,: N C, 1. CH2. CH,); 1.27 (6H, singlet,) „
Example 10., 4-bis (Pivaloyloxy) phenyl -2- (2- (N-6eH3omi-N- -methylglycyl) amino -1,1-dimethylethylamino | ethanol bromohydrate as a foam (yield 10%), t. mp 219-220 s; NMR (cf): 9.0-8.0 (3N, complex, NHCO + + NH2); 7.6-7.1 (8H, complex, aromatic n); 6.2 (1H , wide, SNON);
4.93 (1H, broad, SNON); 4.2 + 3.95 (2H, two singlet,); 3.7-2.7 (complex, CH N + HiO); 2.95 (SN, singlet, CHjN); 1.3 (24H, singlet, jCHjC),
Example 11. 1- (2-Chlorophenyl) -2-f2-C (N-benzoyl-N-methylglyl yl) amino -1,1-dimethylethylamino ethanol bromine-hydrate as a foam (13% yield), so pl. l - 132 C; NMR (d); 9.0-8.0 (Z. H, complex, NHCO + NH); 7.9-7.0 (9n, complex, aromatic H); 5.25 С1Н, doublet / Г 8 С / S /, SNONZ; 4.1 + 3.9 (2H, 2 singlet); 4.0-2.7 (CHP complex, CHjN); 2.9 (SN, singlet, CHjN); 1.3 (6H, singlet, SNEC).
Example 12. 5-bis (Pivaloyloxy) phenyl -2-2-CN-phenoxyacetylprolyl) amino -1,1-dimethylethylamino ethanol hydrobromide as a foam (yield 20%); (cG): 8.7-8.1 (OG, complex, NHCO + NH); 7.4-6.7 (8H, complex, aromatic H); 6.3 (1H, broad, SNON); 4.95 (1H, broad, SNON); 4.78 (2H, singlet, PhOCH CO); 4.32 (1H, complex:; N-CH-CO); 3.7-2.7 (complex,); 2.2-1.7 (4H, complex, X N CHiCHjCHi).
Example 13. 4-bis (Pivaloyloxy) fensh1 -2- (2- I (N -phenoxy-acetyl-N-methylglycyl) amino -1,1-dimethyl: tylamino1 ethanol hydrobromide as a foam (yield 8%) , mp 100-105 ° C; NMR (s /): 8.8-8.0 (3N, complex, NHCO + NH); 7.5-6.7 (8H, complex, aromatic H); 6.2 (1H, singlet, HON); 4.9-4.8 (MN, complex, CHOH + PhOCH CO); 4.15+ + 4.02 (2H, 2 singlets,);
3.6+ 2.7 (complex, +); 3.1+ + 2.87 (2 singlets, CHjN); 1.35 (24H, singlet, CHjC). ,
Example 14., 5-bis (Pivalo-yloxy) phenyl -2-2 (N-benzoylpiperidin-2-ylcarbonyl) amino -1,1-dimethyl-ethylamino ethanol hydrobromide as a foam (yield 16%); NMR (:): 9.0 - 8.0 (MN, complex, NHCO + NHj); 7.7-6.8 (8H, complex, aromatic H); 5.0 1H, doublet / T 8 C / S /, CHOHJ; 4.72 .7 (complex, СО.ОН. N; +); 2.0-1.0 (6H, complex, СNCH CHjCH CH ,,) 1.33 (24H, singlet, СНзС).
Example 15. 4-bis (Pivalo-yloxy) phenyl -2 -2- (N-benzoylpiperidine-2-carbonyl) amino -1,1-dimethyl-ethylamino 1 ethanol bromo hydrate as a foam (yield 5%); NMR (rf): 7.9 - 7.6 (ZN, broad, NHCO + NH,); 6.7 - 6.1
913181
(8H, multiplet, aromatic); 5.3 (1H, broad, singlet, SNON); 4.2 3 .8 (2H, complex, CHOH + N-CH-CO); 3.0-2.8 (complex CHjN + HjO); 1.7-1.1 (ZON, complex, CHjC NCHjCHjCH, Cl4). five
Example 16. 1-СЗ- (Isobutyryloxymethyl) -A- (isobutyres) phenylJ--2-2- ((N-phenoxyacetyl-N-methylglycyl) -amino -1,1-dimesh1ethylamino ethanol bromohydrate as foam (yield 16%); NMR (8.7 - 8.0 (GN, complex, race + NHj); 7.7 - 6.7 (8H, complex, aromatic H); 5.1 - 4.7 (5H, muzzlelet, SNON + PhOCHj); 4.18 1, 04 (2H, 2 singlets, COCHIN); 3.8 - 2.6 (complex, CHjN + HjO); 3.08 + 1.86 (ЗН, 2 singlet,); 1.3 - 1.05 (18 N, multiplet, CH, C).
Example 17, (Isobutyryloxymethyl) -4- (isobutyrsloxy) phenyl 3 -2 -2 (N-benzoylpiperidine 2-carboxy 1) amino (-1,1-dimethylethylamino ethanol hydrobromide as a viscous oil (yield 6 %) NMR (G): 8.5 - 7.8 (MN, complex, MISS + NH); 7.6 - 6.9 (8H, complex, aromatic H); 5.2 - 4.7 (complex , CHjO + CHON + HiO; 4.5 - 1.4 (complex, CHg +) CHCO +; NCKj CH iCHjCHi); 1.25 - 1.10 (18H, 2 doublets + singlet, CHjC).
Example 18. 4-bis (Pivalo-yloxy) phenyl -2- {2- (L-benzoyl-L-methylphenylalanyl) amine -1,1-dimethyl-ethylamino ethanol hydrobromide as a foam (yield 22%); HMP (d): 8.9-8.1 35 (3N, complex, NHCO + NH); 7.6 - 6.7 (13H, complex, aromatic H); 4.96 GN, doublet / T 8 C / S /, 4.55 (1H, triplet, CO.CH.CH, jPh); 3.47 ++ 3.38 (OG, 2 singlets, CHjN); 3.6 2 .6 (6H, complex,, COCHCHjPh); 1.28 (24H, singlet, CH3).
Example 19, 4-bis (Pivalo-yloxy) phenyl -2- {2 (N-phenoxy-acetyl-—H-methyl-; 1-alanyl) amino -1,1-dimethyl-ethylamino ethanol hydrobromide as peyas (yield 8%); NMR (s): 8.7 7 .7 (3N, complex, NHCO + NH); 7.5 - 6.7 (12H, complex aromatic H);
4.9- 4.7 (ЗН, complex, CHOH + PhOCH-); 3.9 - 2.7 (complex, CH, N); 3.0 + 2.83 (2 singlets, CHjN); 1.3 (24H, singlet, CHjC).
Example 20, 4 — bis (pybaloyl-yloxy) phenyl-2-2 (M-benzoyl N-methyl-55-isoleucyl) amine -1,1-dimethylethylamino-ethanol bromohydrate as a foam (yield 24%); NMR (): 9.3 - 8.1 (ZN,
thirty
40
45
50
.
51
ten


five
five
0
0
five
0
complex, NHCO + W,); 7.7 - 7.0 (8H, complex, aromatic H); 5.0 P1H, doublet / T 8 C / S /, 4.5 - 2.7 (complex, + -CO.CH.N); 2.9 (singlet, CHjN); 2.0 (complicated); 1.35 + 1.2 + (32H, 3 singlet, (CHj) jC- + CisCH Et + (CH3) jCi :.
Example 21o 1-C3, 4-bis (Pivalo-yloxy) phenyl -2- {2-С (M-benzoSh1-N-methyl-alanyl) amino -1,1-dimethlethyl-amino | ethanol hydrobromide as a solid (13% yield); ToPL. / v –200 С (decomposition); NMR (/ 0: 8.9 - 8.1 (3N, complex, NHCO + NH); 7.6 - 7.0 (8H, complex, aromatic H);
3.7-3,0 (4H, complex,); 2.9 + + 2.88 (OG, 2 singles,); 1.45+ + +, 30 (27H, 2 singlet, CHjC).
Example 22 1-C3, 4-bis (Pivaloyloxy) phenyl 3-2 -2- (K-benzoyl-acetidine-2-carbonyl) -amino) -1,1-dimethylethylamino ethanol hydrobromide as a foam (yield 10 %), so pl. 130 - (s): 8.8 - 8.0 (2H, complex, NHj); 7.9 (1H, triplet, NHCO); 7.8-7.0 (8H, complex aromatic
. H); 5.0 (2H, complex, CHOH + —CO.CH.N C); .4.2 (2H, multiplet, N);
3.8- 2.8 (complex,); 2.6-2.0 (complex, N, jCHCO).
Example 23. 1-C3, 4-bis (Pivapooyl) phenyl -2-2- (K-chlorobenzoyl-β-prolch1) amino-1.1,1-dimethylethylamino I ethanol hydrobromide as a foam (yield 10%), etc. 120-124 ° C; NMR (/): 8.4 (OG, complex, NHCO + NH); 7.7 - 7, .1 (7H, complex, aromatic H); IH, doublet / T 8 C / S / 4.40 (1H, singlet, NCHCO); 3.9 - 2.8 (6H, complex ,, - observed after treatment with d - AcOH); 2.2 - 1.6 (4H, complex,) NCHjCHjiCHi); 1.3 (24H, singlet, CHjC).
Example 24. (Pivaloxyloxy) phenyl -2- 2- (N-benzoylprolyl) - -amino -1,1-dimethylethylamino ethanol Bromohydrate as a solid (13% yield), mp. 153-158 ° C; NMR (): 8.6 - 7.7 (EZ, complex + triplet, NHCO + NHj); 7.7-6.8 (9H, complex, aromatic H); 6.45 (1H, broad, SNON); 4.8 1H, doublet / T 8 C / S /, 4.4 (1H, complex, JNCHCO); 3.8 - 2.7 (complex, + + EP); 2.3-1.7 (4H, complex,; 1.3 (15H, singlet, CH3C).
Example 25. 4-bis (nor.- -Butyryloxy) phenyl -2-2 (L-phenoxy I
and 1318151 12
acetyl-prolyl) aminoT 1,1-dimethylethyl use a suitable acid and 1,2-di | ethanol hydrobromide in the form of penamino-2-methylpropane: (5% yield), so pl. 93-95 C; NMR): N - (2-amino-2-methylpropyl), 7-8.0 (OG, complex, NHCO + NH); -benzoylpiperidine-2-carboxamide (for
7.4-6.6 (8H, complex, examples of examples 6, l4, 15, and 17) are allocated to the cue H); 6.15 (1H, broad, SNON); in the form of oil; NMR (SOSTS) sG: 7.6 - 7.2 4.85 + 4.70 OG, doublet C / S / + (5H, complex, aromatic Self); 5.8 singlet, CHON + PhOCH, 4.22 (1H, 5.3 (1H, broad, SSS); 3.6 - 2.3 multiplet, NCHCO); 3.9 - 2.7 (complex- (5H, complex,) NCHCO + CHj); 2.27 ny, CHjN + HjO); 2.45 (multiplet, (singlet, ... NH); 2.0 - 1.0 (complex, COCH2CH, CH); 2.2 - 1.7, 1.6 (8H, shi-N); 1, 22 + 1.14 (6H, 2
 Roar, complex + multiplet NCH, jCHj, CH, j + singlet,);
+ WITH SNGSN SNR; 1.22 (bN singlet, N - (2-amino-2-methylpropsh1) -H-b- CHjC); 9.9 (6H, triplet, COCHjCHj CHj). zoylproline (for examples 7.8 and
II p and mep 26o, 4-bis (Pivalo-24) is isolated as a foam; NMR (CDCl1)
yloxy) phenyl -2- {2 (N-4-chlorophenyl-f: 7.6 - 7.2 (6H, complex, aromatic 1-prolyl) amino -1,1-dimethylethylamine H + NHCO); 4.6 + 4.55. (ZN, Tino1 ethanol hydrobromide in the form of a foamy + singlet,) NCHCO + NHj); 3.6 (yield 14%); mp 109-111 ° C; NMR (/ 0: 2.8 (4H, complex, CHjN); 2.5 - 1.7
8.7 - 8.0 (ЗН, complex, NHCO + NH); (, complex, N CHjCHj CHj); 1.05 (6H,
7.6-7.0 (7H, complex, aromatic-singlet, CHjC);
cue N); 6.24 (1H, broad, SNON); (2-amino-2-methylpropyl) -N -ben 4 .88 C1H, dUplet /, T 8 C / S /, ZION; zon-N-methylglycinamide (for example 14, 26 (1H, multiplet, NCHCO; 3.9 -2.7, Ditch 10 and 11). It is isolated as an oil;
T, 68 (complex, + singlet, + NMR (CDCy 7.7 - 7.1 (6H, complex CHjN +); 2.3 - 1.5 (4H, complex, aromatic H + SSS); 4, 1 (2H,
Ny, N СНлСН, СН,); 1.3 (24H, sin singlet, W); 3.3 - 3.0 (4H, add CH 2 C). ny); 2.05 (SA, singlet,);
Example 27., 4-bis (11iva-, 1.05 (6H, singlet, CH3O. lo-IOx) phenyl -2-t2-t (N-benzo-IH-N- (2-amino-2- methylpropyl) -r-me- -norm.-butsIglycyl) amine -1,1-dime "" -N -Phenoxyacetylglycine amide (for tytilamino ethanol bromohydrate of type 16) is isolated in the form of oil; de foams (18% v), mp 175-180 0 (CDClp cL: 7.4 - 6.7 (6H, complex- (decomposition); NMR (): 8.8 - 8, aromatic H + NHCO); 4.73 (MN , complex, NHCO + sp; 7.7 - 7.0 35 (2H, complex, PhOCH); 4.0 (2H, syn- (8H, complex, aromatic H); 4, H,); 3.2 - 2.8 (4H, complex, (complex, SNON +); 4.1 3.95 (2H,); 2.35 (ZN, singlet,). 2 singlet, COCHIN s; 3.7 - 2, 7 (6H, N - (2-amino-2-methylIppropil) -N-ben-complex,); 2.0 - 1.0 (31 Piled-N-zoil -metilfenilalaninamid (for ny + s, SNzS + CHjCH CHiN) Example 18) was isolated as a foam;.
NMR (CDCl1): 8.2 + 7.75 (1H, 2
PRI me R 28., 4 bis (Pivalo-triplet, NHCO); 7.6 - 6.9 (10 N, folded) of finsl} -2-2- (N-thr. -Butyl, aromatic H); 5.4 (1H, Shisicarbonyl-N-methyl-apanyl) amino -1,1-rich NCHCO); 4.4 (2H, singlet,
-dimethylethylamino ethanol bromohydrate (NH); 3.7 - 2.6 (7H, complex, PhCHj +
in the form of foam (yield 10%); NMR (a: + CHiN +); 1.2 (6H, singlet,
9.3 - 7.7 (3N, broad, CONH + NH));
7.5- 7.1 (3N, complex, aromatic N - (2-amino-2-methylpropyl) -N-me-H); 6.5 - 6.0 (1H, broad, SNON); thyl-N -phenoxy-hedetyl / l-alaninamide
4.7-4.3 (1H, wide quartet, (for example 19) are isolated as the mass-COCHNCHj); 4.2 - 2.9 (broad, CH N + la; NMR (CDClj): 7.5 - 6.7 (6H,
+); 2.8 (SN, singlet, NCHj); 1,6-complex, aromatic H + NHCO);
1.0 (36H, CHjC +) .4.8 + 4.63 (2H, 2 singlets, PhOCHj);
Required starting materials,, 65 (2H, triplet, COCH CHjiN); 3.05
can be obtained using the same pro- (5H, complex, CHjN +); 2.36
the procedure that was described in example 1 (2H, triplet,); 1.33 (2H,
to obtain an N- (2-amino-2-methyl-propollet, NH); 1.02 (6H, singlet,
drank) -K-phenylacetyl-prolinamide, is-CH C);
(2-amino-2-methylpropyl) -K-benzoyl-L-methyl eoleucinamide (for example 20) is given in the form of an oil; NMR (CDClg): 7.7 7.0 (5H, complex, aromatic H); 5.9 (1H, broad, 5 NHCO); 4.7 +4.6 (2H, 2 singlet, / NCHCO); 3.4 - 2.7 + 2.9 (7H, complex + singlet, CHjNH + NH, +); 2.1 (complex, CHjCHCHjCHj); 1,, 8 (14H, complex, CHj.C + CHjCHCHjjj); 0
(2-amino-2-methylpropyl) -K-benzoyl-N-methylalaninamide (for example 21) is isolated as an oil, NMR (CDCl) (f, 7.7 - 7.1 (6H, complex, aromatic H + NHCO); 5.2 1H, broad, 5
) NCHCO); 3.6 - 2.9 + 2.95 5H, complex, + singlet / T 7 C / S / + doublet / C / S / + singlet, NHj + CHCH3 + + CHjCJ;
N (2-amino-2-metsh1propyl) -N benz-20 sosh1-acetidin-2-carboxamide (for example 22) is given in the form of an oil; NMR (CDCl1): 8.0 - 7.3 (6H, complex, aromatic H + MSO); 5.05 (1H,
multiplet, NCHCO); 4.23 (2H, multi-K- (4-Chlorobenzo-typlet, N CHCH, jCH2); 3.2 (2H, multiplet, CHjNH); 2.5 (2H, complex, NCHCH CH); 1.45 (2H, singlet, br; 1.1 (6H, singlet,);
H - (2-amino-2-metsh1propyl) -K (- -chlorobenzoyl) -prolinamide (for example 23) is isolated as an oil; NMR (CDCl1) 1 /: .7.8-7.2 (5H, complex, aromatic H + NHCO); /4.7 (рркий, NCHCO); 3.8 - 3.2 (4H, complex- 35 N-Methyl-N- (phen, CHjN); 2.5 - 1.7 + 2.3 (bN, complex oxiacetyl) ny + singlet, HNg ); 1.15 (6H, singlet,);
N - (2-amino-2-methylpropyl) -N - (4- -chlorophenyl-acetyl) -prolinamide (for example 26) was oiled;
NMR (DClj) c /: 7.7 (1H, triplet,: NHCO); 7.4 - 7.0 (4H, complex, aromatic H); 4.4 (1H, compound NCHCO); 3.9 - 2.8 + 3.65 + 3.1 (8H, 45 complex + 2 singlets, CH, j N + PhCHtCO + NHj); 2.2 - 1.7 (4H, complex, NCHjCHjCHj); 1.0 (6H, singlet, CHjC); (2-Amino-2-methyl-propyl) -N benz-norm-butylglycinamide. (for example 27) is in the form of an oil; NMR (CDCI P i 7.7 - 7.4 (6H, complex, aromatic H + NHCO); 4.15 (2H, singlet, N); 3.7 - 3.1 (4H, complex, NHCHJ + CCH; , 1.93 (2H, singlet, NH); 1.9 - 0.8 + + 1.2 + 1.0 (13H, complex + 2 singleN - (2-amino-tert. Tbytoxic ninamide (for the direct form of ; NMR (1H, CONH); 5.0 years, NCHCO); 3, years, NHCH); 2, 2.1 (singlet, N complex, CHjC),
The necessary analogies with the N-F example 1, but n amino acids and are also indicated n
N-benzoylproline
il) proline
N-Benzoyl-azetidine-2-carbox-30-new acid
N-benzoyl-N-metsh1glitsil
glycine
N-Benzoylpiperidine-2-carboxylic acid
55
Getting -b on.
Methyl iodide (sodium (40.32 g of mineral oil, the miscible solution at (54.0-g) in tetra and dimethyl forms is heated to
vani 80 ° C in ATM and hold in
that
cn c
N CH CHCH CHj);
N - (2-amino-2-methylpropyl) -N - -tert.bytoxycarbonyl) N -methylalaninamide (for Example 28) was isolated as a resin; NMR (CDCl1) 7.1 - 6.5. (1H, CONH); 5.0 - 4.3, (1H, multiplet, NCHCO); 3.3 - 3.0 (1H, multiplet, NHCH); 2.85 (SN, singlet, SI, N); 2.1 (singlet, NH); 1.7 - 1.0 (15H, complex, CHjC),
Necessary acids are obtained by analogy with N-phenylacetyl-proline in Example 1, but starting with the appropriate amino acid and acyl chloride (Table 1 also lists some of their properties.
Table 1
N-benzoylproline 157-159 EtOH
K- (4-Chlorbenzo-
-Methyl-N- (phenoxyacetyl)
il) proline
N-Benzoyl-azetidine-2-carboxylic acid
N-benzoyl-N-metsh1glitsil
130-132 Toluene
112-114 Toluene
103-105 Benzene


-
145-147 EtOAc
118-120
Toluene / Pertrol. ether (60-.
45
55
Preparation of -benzoyl-N-methylthiolanine.
Methyl iodide (140 ml), then sodium hydride (40.32 g, 50% w / w in mineral oil) is added to an agitated solution of N-benzoyl-N-alanine (54.0-g) in tetrahydrofuran (700 ml) and dimethylformamide (70 ml). The mixture is heated to a reflux temperature of 80 ° C in an atmosphere of dry argon and held under these conditions in 1515
24 hours and then evaporated. Ether (50 ml) was added to the residue and the mixture was triturated to remove residual methyl iodide. The resulting residue was partitioned between ethyl acetate (230 ml) and water (250 ml). The aqueous phase is extracted with ethyl acetate (2 x X 250 ml) and the combined organic phases are washed with water (250 ml), then with saturated sodium chloride solution (250 ml) and then dried (and evaporated. The residue contains two kinds of transparent immiscible oils.
The lower oil (K-benzoyl-N-methylalanine methyl ester, 40.0 g) is separated and stirred for 16 hours with a mixture of an aqueous solution of sodium hydroxide (W, 800 ml) and tetrahydrofuran (800 ml) . The tetrahydrofuran is then removed by evaporation. The aqueous residue is extracted with ether (2 x 250 ml), cooled to 0 ° C and acidified to pH 2 with 4m hydrochloric acid. The mixture is extracted with ethyl acetate (3x250 mp). These extracts are combined, dried (MgSC4) and evaporated to give N-benzosoh I-N-methylalanine as


solids (38.0 g, mp. 126-127 C after recrystallization from water).
Using a similar procedure.
but starting with the corresponding amino acid of the formula (R
H) and methyl iodide or nor-butyl iodide, the compounds shown in Table 2 are obtained. 2
Compound
Y-Benzoyl Isoleucine 117-119 (recrystallized from water) Y- (Benzoyl) phenylalanine 142-143 Y- (Phenoxyacetyl) - (5-alanine 118-122 N-Benzoyl-Alanine 129-140
Glyoxal raw materials are prepared in the same manner as 3,4-β-bis (pivaloyloxy) fensch-glyoxal in Example 1, by oxidizing with the corresponding 2-bromoacetophenone dimethylsulfoxide (which is obtained by broming the corresponding acetophenone); they have the following properties:
3, 4-bis (normo-butyryloxy) phenyl glyoxal is given as an oily hydrate; NMR (CDCl 3) 8.0 (2H, multiplet, aromatic H); 7.3 (1H, multiplet, aromatic H); 6.27 (1H, broad, DREAMS); 4.0 - 5.0
sixteen
table 2
137-140
121-123
EtOAc
EtOAc (b enzin (60-80 C)

112-114
EtOAc
(petrol)
(60-80 ° C)
Nt.-Butyloxy-carbonyl-N-methylalanine
NBenzoyl-N- (norms o - -butyl) glycine

Some of the amino acid starting materials () are obtained by acylation of the appropriate amino acid () and acyl chloride using the same procedure as described for H-phenylacetate 1 in Example 35, which have the following properties:
M.p. WITH
(2H, broad, SNON); 2.52 (4H, triplet, COCHjCH CH j); 1.76 (4H, sextet,); 1.02 (bN, triplet, COCH,);
4-pivaloyl-oxyphenylglyoxal is isolated as its oily hydrate; NMR (CDClI) cf: 8.15 - 7.2 (4H, multiplet, aromatic H); 7.5 - 6.5 (AH, broad, SNON); 1.36 (9H, singlet, CHjC);
3, 5-bis (pivaloyloxy) phenylglyoxal is isolated in the form of its vitreous hydrate; NMR (CDC1 j), 6 (2H., Multiplet, aromatic H); 7.4 - 7.1 (1H, multiplet, aroma
1713
ches H); 6.5; 5.8 (1H, complex CHOH); 5.2 (2H, broad singlet, SNON) .; 1.5 (18H, singlet,
2-chlorophenylglyoxal is isolated as its vitreous hydrate; NMR (CDCl1) f: 7.8 - 7.1 (4H, complex, aromatic H); 6.2 - 5.85 (1H, | 4 multiplet, SNON); 3.8 (2H, broad singlet, SNON).
PRI me R 29. Using the procedure described in Example 1, but using 3, 4-bis (pivaloyloxy) phenylglyoxal and 2-and (H-phenylacetyl-prolyl) amino-ethyl amine as starting material, 1- C3, 4-bisCpivaloxy) phenyl -2-2-C (H-phenylacetyl-propyl) amino ethylamino-ethanol bromohydrate as a foam (yield 15–20%); NMR (/): 8.7 - 8.2 (3N, NHCO and NH complex); 7.4 - 7.0 (9H, complex, aromatic H + OH); 4.9 (1H, broad, SNON); 4.25 (1H, multiplet, NCHCO); 3.8 - 2.8 (YUN, Complicated, CH N + PhCHj); 2.2-1.7 (4H, complex, N CHjCHjCHj); 1.25 (18H, singlet,).
The necessary starting material is prepared as follows.
N-phenylacetyl proline (53.0 g) was added in portions to a stirred solution of thionyl chloride (18.0 ml) in methanol (96 ml), which was maintained at a temperature of −5 ° C. After the addition is complete, the reaction mixture is kept at room temperature for 3 days and then you have 4, 3. - NVG
2С 35 Н eKzOe НВг ЗН ,, 0
3Сз, H.NjOvHBr
4С „Н ,, N404015.-НВг
6 With Nz ,, YzOzS1. NVG
7Cj, H.NjC, -NBg
8C 14 Hjo NjOjCl HBg
5118
they give. The residue is suspended in water (24 ml), the solid potassium carbonate is neutralized and extracted with ether (3 X 200 ml). The extracts are washed with water (200 ml), dried (MgSO4) and evaporated to give the N-phenyl acetate-β-proline methyl ester as a solid (51.1 g) (mp 71-72 ° C. after recrystallization from cyclohexane).
A mixture of methyl ester (49.1 g) and 1,2-diamino-ethane (35.76 g is heated to 95-100 ° C, which is maintained for 24 hours. Excess diamine is removed by stirring and the residue is mixed with water. separated by filtration and the aqueous phase is evaporated. The remaining traces of water are removed by co-evaporation with toluene, yielding 2-f (M-phenylacetate 1-prolyl) amino ethylamine as a solid (58.9 g), which is used without subsequent cleaning.
The final products of examples 1-29, obtained by the proposed method, were characterized on the basis of their spectrum of nuclear magnetic resonance (m) and the identity of the starting materials. In some cases, microanalysis of elemental nitrogen has also been used to confirm the empirical formula of the final product.
The results of microanalysis are shown in Table. 3
6.0 5.5 5.7 9.2
7.7 6.9 7.8
Tests on the biological activity for the entire group in the value of scrap. The result obtained was then followed by the activity of compounds of the formula Iwali with an increase in the weight of
As a local anti-inflammatory, compared to the left ear
The gel agents can be a demonstration-control group of 10 smaller ones, which is as follows. ... dyes obtained croton oil and this solution was prepared with 4% solution solution without test compound, (vol / vol) croton oil c. The percentage of inhibition, inflammation,
acetone. A portion (10 ml) of this soluble croton oil was
injected into the right ear of a mouse — albi. counted for test compound, nose (Alderley fark st-rain, svob-). This procedure was repeated with
from a specific pathogen). By using a different concentrate, a portion (10 ml) of the test compound was immediately injected to work the test compound, depositing the amount of the test compound with ethanol into the same ear. The procedure of inhibiting the ear was inflamed on ten mice. After 4 hours at 50% () „
the mice were killed, both ears were removed- Using the procedure were obtained
us and weighed. Increased results were determined with a compound of formula I
weight of the right ear as compared to / test in the form of its bromide-dvG for each mass and the preparation of medium salt was obtained (see Table 4). T a b i c a 4.
3, A-Pivaloyloxy
(3-lPrCOj CH (4-lPrCO
Spill-b spill-l
PhOCH ,, CO
PhCH, CO
13
four
Note.
for examples 1-28 K K CHj and for example 29 R R N.
2313
Using the same test procedure, it was determined that 4-cyano-A, 4-dioxy-5.5-dimethyl-3,3-triphenylmethanedicarboxylic acid compounds, which are known to have local anti-inflammatory properties, have LDgg 230 mg / ear, i.e. significantly inferior in their effectiveness to the proposed compounds.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining derivatives of 1-phenyl-2-aminoethanol of the general formula
R CH (OH) CHjNHCR to CHjNHCOCHR A,
where r is. 3,4-or 3,5-bis (pivaposh1oxy) phenyl, 4-pivalosh1oxyfe-NIL, 3-isobutyrylximethyl-4-isobutyryloxyphenyl, 3, 5-dichloro-4-aminophenyl or 3,5-bis (n-butyryloxy) phenyl;
R and hydrogen or methyl;
 hydrogen, C-C-alkyl, benzyl C-C-alkyl or R and R form C, 2-C-alkylene,
Editor N. Kishtulints Order 2439/57,
Compiled by V. M Kusheva
Tehred N.Glushchenko Proofreader M. Sharoshi
Circulation 372Subscribe
VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, Proektna str., 4
51
24
five
five
0
five
A is a simple bond or methylene; Q - phenylacetyl, phenoxyacetyl, benzoyl, 4-chlorobenzoyl; 4-chlorophenylacetate 1, tert-butyloxycarbonyl,
or their pharmaceutically acceptable salts, characterized in that the glyoxal of the general formula
R-C-G-H II II
00
where R has the indicated meanings, is reacted with an amine of the formula
IHoCCHoNHC CH-A-N-Q
VV - II I I
R V 0 C RS
where R, R, R, R, A and Q have the indicated meanings, in the presence of sodium cyanoborohydride in an organic solvent medium, followed by isolating the desired product or translating it into a pharmaceutically acceptable salt.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US4303649A|1981-12-01|1-Phenyl-2-aminoethanol derivatives

---

RU2084453C1|1997-07-20|Method of synthesis of aromatic derivatives or their salts with organic or inorganic acids or their racemates

---

KR100287749B1|2001-04-16|Opioid diarylmethylpiperazine and piperidine

---

CA2552565C|2013-12-31|Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

---

EP0559538B1|2000-05-17|Quaternary salts of 4-substituted piperidines, their preparation and pharmaceutical compositions containing them

---

US4999377A|1991-03-12|Chemical compounds

---

US5686622A|1997-11-11|Thiazolidine derivatives, their preparation and the medicaments containing the same

---

IE60887B1|1994-08-24|Amide derivatives

---

SU1318151A3|1987-06-15|Method for producing 1-phenyl-2-aminoethanol derivatives or pharmaceutically acceptable salts thereof

---

HU0105073A2|2002-04-29|2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them

---

JPH09512528A|1997-12-16|Benzamide derivatives as vasopressin antagonists

---

AU620583B2|1992-02-20|New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same

---

EP0583485B1|1997-08-13|Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities

---

CA2072981A1|1991-08-10|N-phenyl n-acetamido glycinamides, their preparation and drugs holding same

---

EP0995436A2|2000-04-26|Ligands for sigma receptors and their therapeutical applications

---

US6498196B1|2002-12-24|Compounds useful in pain management

---

AU2006270914B2|2011-01-20|Substituted propanamide derivative and pharmaceutical composition containing the same

---

EP0551034A2|1993-07-14|Cephalosporins having in position 7 a benzyloxyimino radical substitute, process for their preparation and their use as medicaments

---

JPH09328469A|1997-12-22|New substituted acetamide compound

---

US20040063785A1|2004-04-01|Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly | glycohydrolase, and methods for their use

---

EP1165528A1|2002-01-02|Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives

---

JPH08283220A|1996-10-29|N-arylalkylphenylacetamide compound

---

EP0000809B1|1982-04-14|Anti-inflammatory 1-phenylethanolamine derivatives, pharmaceutical compositions thereof and processes for their manufacture

---

EA001887B1|2001-10-22|Imino-aza-anthracyclinone derivatives for the treatment of amyloidosis

---

JPH05117236A|1993-05-14|Dichloroaniline compound

同族专利:

---

公开号 | 公开日

---

PL128750B1|1984-02-29|

---

NZ193560A|1982-05-31|

---

DE3061410D1|1983-01-27|

---

IL60007A|1984-06-29|

---

IE49772B1|1985-12-11|

---

PT71283A|1980-06-01|

---

PH17143A|1984-06-04|

---

EP0019411B1|1982-12-22|

---

ZA802552B|1981-04-29|

---

JPS55154948A|1980-12-02|

---

DD150892A5|1981-09-23|

---

AU542577B2|1985-02-28|

---

NO151237B|1984-11-26|

---

US4323575A|1982-04-06|

---

CA1149804A|1983-07-12|

---

IE800871L|1980-11-21|

---

AU5800080A|1980-12-11|

---

ES491643A0|1981-04-16|

---

IL60007D0|1980-07-31|

---

NO151237C|1985-03-06|

---

GR68464B|1981-12-30|

---

HU180139B|1983-02-28|

---

AT2070T|1983-01-15|

---

NO801491L|1980-11-24|

---

CS212715B2|1982-03-26|

---

DK221280A|1980-11-22|

---

EP0019411A1|1980-11-26|

---

ZW9580A1|1981-12-23|

---

FI801632A|1980-11-22|

---

ES8104187A1|1981-04-16|

---

PL224366A1|1981-02-13|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1178400A|1966-12-13|1970-01-21|Delalande Sa|Nitrogen Substituted Amines and their process of Preparation.|

---

US3607859A|1968-06-12|1971-09-21|Monsanto Co|Furylacryloylgly-clycyl-l-leucinamide and relateo peptides and use thereof in spectrophotometric assay for neutral protease|

---

US4041075A|1973-12-12|1977-08-09|Imperial Chemical Industries Limited|Phenoxy-alkanolamine derivatives|

---

GB1460593A|1973-06-22|1977-01-06|Ici Ltd|Ethanolamine derivatives|

---

GB1468156A|1973-07-19|1977-03-23|Ici Ltd|Phenylethylamine derivatives|

---

US3957870A|1973-07-19|1976-05-18|Imperial Chemical Industries Limited|Organic compounds|

---

DE2557657A1|1975-12-20|1977-06-30|Knoll Ag|NEW SPERMINE DERIVATIVES|

---

GB1540463A|1976-10-07|1979-02-14|Ici Ltd|Alkanolamine derivatives|IE54220B1|1981-12-23|1989-07-19|Ici Plc|Phenol esters|

---

US4574129A|1984-01-31|1986-03-04|Bristol-Myers Company|Topical nonsteroidal anti-inflammatory methods|

---

US4540581A|1984-01-31|1985-09-10|Bristol-Myers Company|Topical nonsteroidal anti-inflammatory compositions and uses|

---

JPH0479334B2|1984-07-31|1992-12-15|Suntory Ltd|

---

AU5410786A|1985-03-04|1986-09-11|Fujisawa Pharmaceutical Co., Ltd.|Amino acid derivatives and processes for preparation thereof|

---

JPH0623190B2|1985-04-16|1994-03-30|サントリー株式会社|N-acylpyrrolidine derivative having inhibitor activity, process for producing the same and use thereof|

---

US4636405A|1985-12-24|1987-01-13|Corning Glass Works|Curing apparatus for coated fiber|

---

EP1125925A1|2000-02-15|2001-08-22|Applied Research Systems ARS Holding N.V.|Amine derivatives for the treatment of apoptosis|

---

PL212489B1|2008-01-22|2012-10-31|Univ Jagiellonski|Phenoxyalkiloaminoalkanols derivatives and its applications|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB7917645|1979-05-21|

---